In the current investigation, we examined the clinical attributes of TMT1A through a multi-omics approach and substantiated its functional role in vitro and vivo. Our findings revealed that TMT1A exhibits significantly downregulated expression in LUAD and functionally suppresses malignant phenotypes through multiple mechanisms: inhibiting tumor cell proliferation, impeding cancer cell migration, attenuating M2 polarization of TAMs, while simultaneously enhancing T cell activation. The gene discussed is TMT1A; the disease is neoplasm.